Skip to main content

Table 3 Treatment-related adverse events

From: One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma

 

HAIC 2d (n=120)

 

HAIC 1d (n=248)

 

p

p for grade 3–4 AE

Any grade

Grades 1–2

Grade 3

Grade 4

Any grade

Grades 1–2

Grade 3

Grade 4

  

Hypertension

44 (36.7%)

43 (36.2%)

1 (0.95%)

0

83 (33.5%)

79 (31.9%)

4 (1.6%)

0

0.55

1

Fatigue

87 (72.4%)

87 (72.4%)

0

0

99 (39.9%)

98 (39.5%)

1 (0.4%)

0

<0.001

1

Fever

16 (13.3%)

16 (13.3%)

0

0

19 (7.7%)

19 (7.7%)

0

0

0.082

 

Sensory neuropathy

46 (38.1%)

46 (38.1%)

0

0

28 (11.3%)

27 (10.9%)

1 (0.4%)

0

<0.001

1

Edema

15 (12.4%)

15 (12.4%)

0

0

21 (8.5%)

17 (6.9%)

4 (1.6%)

0

0.22

0.31

Alopecia

23 (19.1%)

23 (19.1%)

0

0

10 (4.0%)

10 (4.0%)

0

0

<0.001

 

Abdominal pain

70 (58.1%)

69 (57.1%)

1 (0.95%)

0

128 (51.6%)

121 (48.8%)

5 (2.0%)

2 (0.8%)

0.23

0.4

Nausea

91 (76.2%)

89 (74.3%)

2 (1.9%)

0

140 (56.5%)

137 (55.2%)

3 (1.2%)

0

<0.001

0.66

Vomit

49 (41.0%)

41 (34.3%)

8 (6.7%)

0

75 (30.2%)

61 (24.6%)

14 (5.7%)

0

0.044

0.7

Diarrhea

31 (25.7%)

26 (21.9%)

5 (3.8%)

0

38 (15.3%)

38 (15.3%)

0

0

0.015

0.003

Neutropenia

21 (17.5%)

19 (16.2%)

1 (0.95%)

1 (0.95%)

16 (6.5%)

13 (5.2%)

2 (0.8%)

1 (0.4%)

0.001

0.66

Anemia

83 (69.5%)

82 (68.6%)

1 (0.95%)

0

145 (58.5%)

145 (58.5%)

0

0

0.048

0.33

Thrombocytopenia

58 (48.6%)

56 (46.7%)

2 (1.9%)

0

90 (36.3%)

75 (30.2%)

10 (4.0%)

5 (2.0%)

0.027

0.06

Elevated ALT

84 (70.0%)

71 (59.1%)

13 (10.5%)

0

160 (64.5%)

149 (60.1%)

11 (4.4%)

0

0.30

0.02

Elevated AST

119 (99.1%)

79 (65.7%)

37 (30.5%)

3 (2.9%)

237 (95.6%)

185 (74.6%)

48 (19.4%)

4 (1.6%)

0.13

0.01

Hyperbilirubinemia

57 (47.6%)

56 (46.7%)

1 (0.95%)

0

98 (39.5%)

96 (38.7%)

2 (0.8%)

0

0.15

1

Elevated CRE

11 (9.5%)

11 (9.5%)

0

0

56 (22.6%)

56 (22.6%)

0

0

0.002

 

Hypoalbuminemia

109 (90.5%)

109 (90.5%)

0

0

233 (94.0%)

233 (94.0%)

0

0

0.27

 

Prolonged PT

57 (47.6%)

57 (47.6%)

0

0

63 (25.4%)

63 (25.4%)

0

0

<0.001

 

Grades 3–4

  

56 (46.7%)

  

90 (36.3%)

 

0.056